dm+d
108441004
Articles
Safety in Lactation: Antipsychotics
22 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral and non-depot antipsychotics with less…
What are the clinically significant drug interactions with tobacco smoking?
23 March 2020This Medicines Q&A summarises those drug interactions with tobacco smoking that are considered to be most clinically important. Most interactions between drugs and tobacco smoking…
Medicine Compliance Aid Stability
ZyprexaEli Lilly and Co Ltd
Eli Lilly and Co Ltd
Zyprexa
Tablets f/c 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.
1 October 2015
Zyprexa VelotabsEli Lilly and Co Ltd
Eli Lilly and Co Ltd
Zyprexa Velotabs
Tablets orodispersible 5mg, 10mg, 15mg, 20mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Do not open until immediately prior to use. May disintegrate in moisture in the air.
1 October 2015
genericAccord Healthcare Ltd
Accord Healthcare Ltd
generic
Tablets f/c 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No specific storage requirements.
1 October 2015
genericSandoz Ltd
Sandoz Ltd
generic
Tablets orodispersible 5mg, 10mg, 15mg, 20mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from light and moisture. Orodispersible tablets, therefore hygroscopic.
1 October 2015
Lactation Safety Information
Oral
Oral
Quetiapine, Haloperidol
Moderate published evidence indicates that maternal oral doses up to 20mg daily produce low levels in breast milk
Long half-life increases risk of accumulation in breastfed infants
Occasional adverse effects reported including somnolence, lethargy poor sucking, irritability and tremor
Monitor infant for sedation, poor feeding, behavioural effects, extrapyramidal symptoms, and developmental milestones
17 September 2020
Depot injection
Depot injection
see entry under Olanzapine embonate
17 September 2020
New Medicines
Zyprexa Rapid control of schizophrenia, when oral therapy not appropriate - IM injection
Information
Zyprexa
New formulation
Eli LIlly
Eli Lilly
Development and Regulatory status
Launched
Launched
Launched
May 2022 (re-launched)
May 22Zyprexa injection re-launched in the UK. Price for 10mg/ml powder for soln for inj in vial, 1=£35.95 [4].
Jan 21MHRA issues a GB product licence for Zyprexa injection. All existing CAP MAs have been automatically converted into UK MAs effective in Great Britain (only) and issued with a UK MA number following EU exit [3].
Aug 12Zyprexa injection withdrawn in the UK for sales volume reasons and not for any safety reason. There is no generic or alternative rapid-acting olanzapine injectable formulation available in the UK. It will still be available in other countries outside the UK. Note that the depot injection, olanzapine embonate (ZypAdhera; Lilly) will still remain available in the UK [7].
Apr 04Launched in the US [2].
Mar 04FDA approves ZYPREXA IntraMuscular for the treatment of agitation associated with schizophrenia and bipolar I mania [5].
Feb 04Zyprexa injection launched in the UK and other European countries [2].
Sep 96EMA approves ZYPREXA 10 mg powder for solution for injection for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate [6].
Category
An antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems, including serotonin, dopamine and cholinergic muscarinic receptors. Available as a powder for solution for injection, given as a single injection (10mg, or 5mg or 7.5 mg as clinically appropriate). A second injection, 5-10 mg, may be administered 2 hours after the first injection on the basis of individual clinical status (max 20mg daily).
In the UK the adult psychiatric morbidity survey found that around 0.5% of people aged 16 years or older in England had received a diagnosis of a psychotic disorder (schizophrenia, schizoaffective disorder, or affective psychosis) in the preceding year. Schizophrenia can develop at any age but starts most commonly in adolescence and the early 20s. In young people aged 10-18 it accounts for 24.5% of all psychiatric admissions, with a marked rise after the age of 15 [1].
Rapid control of schizophrenia, when oral therapy not appropriate - IM injection
Intramuscular